The output of sevoflurane from a drawover system utilizing two Oxford Miniature Vaporizers (OMVs) in series has been shown in bench-testing to be predictable. We have shown that adequate anaesthesia can be achieved with one vaporizer in most situations if an intravenous induction is used. Occasionally a second vaporizer is necessary to deepen the level of anaesthesia. For an inhalational technique to be successful it is necessary to use both vaporizers from the outset. Under these conditions, adequate operating conditions are easily produced. The method could be useful in field or military applications.
The OMV as a drawover vaporizer in a suitable circuit (the Triservice apparatus) was first described in 1968 ( Figure 1 ). It was originally intended to deliver a halothane/trichloroethylene anaesthetic by using two OMVs connected in series. It has been used successfully with combinations of trichloroethylene and halothane, isoflurane, or enflurane 1 . Trichloroethylene is no longer commercially available and so more recently one OMV has been used with isoflurane as the sole anaesthetic agent.
Potential advantages of sevoflurane include its rapidity of onset and offset, and also its ease of use as an inhalational induction agent. There has been one study 2 recently published confirming that in bench tests this apparatus is capable of delivering 6% sevoflurane at a respiratory rate of 12 breaths a minute and a tidal volume of 600 ml. There have been no published studies of sevoflurane drawover anaesthesia in a clinical setting.
We postulated that using sevoflurane in one OMV in drawover mode would produce clinically useful concentrations for most situations but that occasionally two OMVs in series would be necessary to provide sufficient volatile agent to produce the required depth of anaesthesia.
METHOD
Ethical approval for the study was obtained from the hospital ethics committee, Royal Hobart Hospital, Tasmania.
We anaesthetized 20 patients using sevoflurane in two OMVs in series. One or other author approached eligible consecutive patients on their lists for enrolment in the study. Informed consent was gained. Patients were excluded if they required paralysis and intermittent positive pressure ventilation, had an ASA grade of greater than 3, if their body mass index (BMI) was greater than 30, if they were on any sedative drugs, or if surgery was expected to last more than one hour. All patients were listed for minor procedures from the following surgical specialities: general surgery (7), gynaecology (6), urology (4), orthopaedics (2), and otolaryngology (1). The ambient temperature in the operating theatres was 22 to 23°C.
Patients were given an inhalational or intravenous induction depending on their expressed preference. No premedications were used. All patients were monitored using standard monitoring: this was a minimum of ECG, NIBP, SpO 2 , EtCO 2 , end-tidal sevoflurane, and FiO 2 . These parameters were recorded automatically every three minutes. The patients were also monitored clinically as usual. We recorded signs of inadequate anaesthesia: coughing/breath-holding, laryngospasm, movement in response to surgery, respiratory rate above 25 breaths per minute, and tachycardia or an increase in systolic blood pressure of 20% above baseline.
Patients in the intravenous induction group were preoxygenated with the oxygen flow set at 8 litres per minute for three minutes, which produced an FiO 2 of greater than 90% in all cases. Each patient then received 1.5 µg/kg fentanyl followed by 3 mg/kg propofol intravenously. An appropriate sized Laryngeal Mask Airway (LMA) was inserted 90 seconds after completion of the propofol injection. Ventilation was assisted if necessary until spontaneous ventilation returned. Sevoflurane was delivered using one OMV turned to its maximum setting until conditions suitable for surgery were achieved. The time taken for this was noted. The oxygen flow was then reduced to 1 litre per minute and the remaining drawover gas was room air.
Patients receiving a gaseous induction were preoxygenated in a similar manner to the intravenous induction group and received the same inhaled drawover carrier gas for maintenance of anaesthesia. One OMV was then turned on to full until suitable intubating conditions were achieved. The time taken for this was noted. Fentanyl 1.5 µg/kg was then administered intravenously, 90 seconds later an appropriately sized LMA was inserted if the patient appeared to be adequately anaesthetized. If signs of inadequate anaesthesia were observed the second OMV was turned to full until adequate anaesthesia was achieved, and then the LMA inserted. They received the same maintenance drawover gas as did the intravenous induction group. The absence of any signs of inadequate anaesthesia during maintenance was the aim in both patient groups. Where possible this was achieved with one OMV, the second only being utilized if signs of inadequate anaesthesia were observed.
If indicated, both groups received 0.1 mg/kg morphine intravenously five minutes after spontaneous respiration returned. No further analgesics were given until the patients were awake in the recovery room. Further morphine was then administered as required according to the acute pain protocol used in our hospital.
Sevoflurane was discontinued when wound closure was complete in both groups. The LMA was left in situ until the patients were awake as demonstrated by eye-opening. The time taken for this to occur was noted.
RESULTS
The majority of patients requested an intravenous induction (16/20). Of these only two demonstrated any signs of inadequate anaesthesia, in both cases this was movement in response to surgical stimulation. The use of the second OMV restored an adequate depth of anaesthesia and no further interventions were required to allow surgery to be completed.
The time taken to achieve adequate anaesthesia and the time taken to eye-opening following completion of surgery were both faster than has been previously reported using either a halothane/ trichloroethylene combination or isoflurane alone 1 .
Only four of the 20 patients studied requested an inhalational induction. All these patients demonstrated signs of inadequate anaesthesia during the induction phase whilst only one vaporizer was turned on. The signs were movement (2), increased respiratory rate (1), and tachycardia (1). Following the use of the second vaporizer all four patients were anaesthetized sufficiently to allow induction to be completed.
There were no clinically significant alterations in the vital signs or oximetry of any patient in the study. The majority of patients required no supplementary analgesia in recovery, two from the intravenous induction group received 10 mg morphine as did one from the inhalational induction group.
DISCUSSION
Drawover anaesthesia provides a simple method of delivering volatile anaesthetic gases in the absence of compressed gases. These systems have been used successfully for many years in military and field situations using the older anaesthetic agents. A recent paper by Liu and Dhara demonstrated a relatively predictable output of sevoflurane from two OMVs connected in series when bench-tested under a wide range of circumstances 2 . We have shown that these predictions can be taken into the clinical setting and used successfully. When using an intravenous induction technique the majority of patients can be adequately anaesthetized using only one vaporizer but there are times when it is necessary to employ a second vaporizer to achieve the required depth of anaesthesia. In order to achieve an adequate depth of anaesthesia using an inhalational induction with this system it is necessary to utilize both vaporizers from the outset. This is as would be predicted from the bench tests.
The pharmacokinetic advantages of sevoflurane can be utilized in this drawover system in the clinical environment. Its wider use in field conditions and in developing countries would be an advance in patient safety as the potentially complicated periods of anaesthesia, induction and time to recovery, are reduced compared to using older agents. The cost of sevoflurane will undoubtedly have to fall before these benefits can be enjoyed by the developing world.
In conclusion, we have demonstrated a useful clinical place for sevoflurane via two OMVs in series for use in field or military anaesthetic environments.
